RJA
PASG icon

Raymond James & Associates’s Passage Bio PASG Stock Holding History

Raymond James & Associates’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,644
Closed -$924K – 4168
2021
Q1 		$924K Buy
2,644
+1,261
+91% +$538K ﹤0.01% 2568
2020
Q4 		$707K Buy
1,383
+458
+50% +$183K ﹤0.01% 2572
2020
Q3 		$243K Buy
+925
New +$318K ﹤0.01% 3083

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Raymond James & Associates's PASG Position: Q2 2021 in Review

Raymond James & Associates sold out of Passage Bio (PASG) in Q2 2021, closing a stake of 2,644 shares — an estimated $924K sold.

Raymond James & Associates first reported a position in PASG in Q3 2020 and held it in 3 quarters. The position peaked at $924K in Q1 2021. 102 funds tracked by Wall St. Rank hold PASG as of Q2 2021.

  • Raymond James & Associates reported no remaining Passage Bio position as of Q2 2021 after selling out during the quarter.
  • Raymond James & Associates sold 2,644 Passage Bio shares in Q2 2021, an estimated $924K.
  • Raymond James & Associates first reported a position in Passage Bio in Q3 2020 and held it in 3 quarters.
  • Raymond James & Associates's Passage Bio position peaked at $924K in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Passage Bio as of Q2 2021.

Based on Raymond James & Associates's 13F filing for Q2 2021, filed 11 Aug 2021.